ro 41-1049 hydrochloride

Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (Kd: 16.5 and 64.4 nM, respectively).

Ro 41-0960 is used as a reversible and orally-active COMT-inhibitor.

Ro 41-1879 is a catechol cephalosporin with antimicrobial activity.

NR2B-containing NMDA receptors antagonist

Ro 32-0432 hydrochloride is a protein kinase C inhibitor.

Ro 41-1049 is a reversible, selective MAO-A inhibitor.

Ro 41-5253 is an orally active RARα antagonist, ligand, and partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ. It exhibits antitumor activity, inhibits proliferation, and induces apoptosis in MCF-7 and ZR-75.1 estrogen receptor-positive breast cancer cells.

Ro 41-3290, the desethylated derivative of Ro 41-3696, is a nonbenzodiazepine partial agonist at the benzodiazepine receptor.

Selective prostacyclin IP receptor antagonist (pKi = 8.3). Exhibits no affinity at other prostanoid receptors (EP1-4, FP and TP) in a radioligand binding assay. Demonstrates analgesic activity in rats. Orally bioavailable. Clark et al (2004) Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists. Bioorg.Med.Chem.Lett. 14 1053 PMID:15013022 |Jones et al (2006) Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations. Br.J.Pharmacol. 149 110 PMID:16880763 |Bley et al (2006) RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br.J.Pharmacol. 147 335 PMID:16331286

CTX-0294885 hydrochloride is an agarose-supported kinase capture reagent.

Ro 363 hydrochloride is an effective, highly selective agonist of β 1-adrenoceptor. Ro 363 hydrochloride is an effective inotropic stimulant. Ro 363 hydrochloride is a cardiovascular regulator, which can reduce diastolic blood pressure and significantly increase myocardial contractility.

Ro 8-4304 hydrochloride, an NMDA receptor antagonist, is a potent chemical compound used in research and clinical settings for its ability to inhibit glutamate-mediated neurotransmission.

Potent trace amine 1 (TA1) receptor agonist (EC50 values are 0.12, 35 and 17-85 nM for mouse, rat and human receptors, respectively). Increases wakefulness and reduces REM and NREM sleep duration in wild type mice. Inhibits spontaneous locomotor activity in dopamine transport (DAT) knockout mice. Espinoza et al (2018) Biochemical and functional characterization of the trace amine-associated receptor 1 (TAAR1) agonist RO5263397. Front.Pharmacol. 9 645 PMID:29977204 |Galley et al (2015) Discovery and characterization of 2-aminooxazolines as highly potent, selective, and orally active TAAR1 agonists. ACS.Med.Chem.Letts. 7 192 PMID:26985297 |Schwartz et al (2017) Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition. Neuropsychopharmacology. 42 1305 PMID:27658486